Trial Profile
An open label,phase I study to evaluate pharmacokinetics, safety and tolerabilty of Glecaprevir and Pibrentasvir in Healthy White, Chinese, and Japanese Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Aug 2017
Price :
$35
*
At a glance
- Drugs Glecaprevir (Primary) ; Pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 18 Aug 2017 New trial record
- 11 Aug 2017 Results of this and one another phase I study published in the Journal of Clinical Pharmacology.